论文部分内容阅读
目的探讨利巴韦林注射液联合痰热清超声雾化治疗流感病毒感染致病毒性肺炎的临床疗效。方法选择2012—2014年湖北省中西医结合医院收治的67例流感病毒感染致病毒性肺炎患者,随机分为观察组34例和对照组33例。观察组采用利巴韦林注射液联合痰热清超声雾化治疗,对照组采用利巴韦林注射液治疗,两组疗程均为2周。比较两组患者临床症状(咳嗽、喘息、发热、全身酸痛等)好转时间,酶学指标恢复正常时间,肺部病灶吸收时间,动脉血气分析指标(Pa O2及SPO2)及不良反应发生情况。结果观察组患者咳嗽、喘息、发热、全身酸痛好转时间短于对照组,酶学指标恢复正常时间、肺部病灶吸收时间短于对照组,总有效率高于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后第3天,第7天Pa O2、SPO2高于对照组,差异有统计学意义(P<0.05)。两组患者治疗期间均未发生明显不良反应。结论利巴韦林注射液联合痰热清超声雾化治疗流感病毒感染致病毒性肺炎的临床疗效显著,可有效改善患者临床症状,不良反应少。
Objective To investigate the clinical efficacy of ribavirin injection combined with phlegm-heat ultrasonic atomization in the treatment of viral pneumonia caused by influenza virus infection. Methods Sixty-six patients with viral pneumonia who were infected with influenza virus from 2012 to 2014 in Hubei Provincial Hospital of Integrated Traditional Chinese and Western Medicine were randomly divided into observation group (34 cases) and control group (33 cases). The observation group was treated with ribavirin injection combined with phlegm-heat ultrasonic nebulization, while the control group was treated with ribavirin injection. Both groups were treated for 2 weeks. The improvement time of clinical symptoms (cough, wheezing, fever, body aches, etc.), the recovery time of enzymology index, the time of pulmonary lesion absorption, the index of arterial blood gas analysis (Pa O2 and SPO2) and the incidence of adverse reactions were compared between the two groups. Results The observation group patients cough, wheezing, fever, body aches and pains to improve the time shorter than the control group, enzymology indicators returned to normal time, pulmonary lesion absorption time is shorter than the control group, the total effective rate was higher than the control group, the difference was statistically significant P <0.05). PaO2 and SPO2 on the 3rd and 7th day after treatment in the observation group were higher than those in the control group, and the difference was statistically significant (P <0.05). No significant adverse reactions occurred in both groups during treatment. Conclusion The combination of ribavirin and phlegm-heat ultrasonic nebulization has significant clinical effect on viral pneumonia caused by influenza virus infection, which can effectively improve clinical symptoms and adverse reactions.